APPLICATION
ANDA214682
TYPE
ANDA
ORIGINAL APPROVAL
2022-02-10
LATEST ACTION
2025-09-17
ROUTE
INTRAMUSCULAR
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
FULVESTRANTPrescription
FULVESTRANT 250MG/5ML (50MG/ML) · SOLUTION · INTRAMUSCULAR
Approval history
2025-09-17Labeling · Supplement 7 · standardAP
2022-02-10UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.